The FDA's move to incorporate Bayesian statistical methods into clinical trials of drugs and biologics garnered special treatment in JAMA this week. UW Professor of Biostatistics Thomas Fleming weighs in with his thoughts.
In the News
Headlines featuring UW Biostatistics people and research.
Are Bayesian Statistics Coming to a Clinical Trial Near You?
MEDPAGE TODAY,
New Podcast Calls Attention to Underrecognized IRGT Trial Design
NIH Pragmatic Trials Collaboratory,
In a new episode of the NIH Collaboratory Podcast, Drs. Jonathan Moyer and David Murray discussed their recent publication, “Evaluating Analytic Models for Individually Randomized Group Treatment Trials With Complex Clustering in Nested and Crossed Designs.” The episode was moderated by Patrick Heagerty, co-chair of the Biostatistics and Study Design core working group and professor of biostatistics at the University of Washington.
Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards
JAMA Perspective,
University of Washington Professor of Biostatistics Thomas Fleming and Affiliate Professor Holly Hanes reflect on the FDA's recently released draft guidance regarding the use of bayesian methods in clinical trials.
The weed-killer wars
The Week,
Trump wants the U.S. to ramp up production of glyphosate. The MAHA movement is furious. Lianne Sheppard, Professor of Biostatistics and Environmental and Occupational Health Sciences weighs in on the herbicide’s safety.
The Math That Explains Why Bell Curves Are Everywhere
Quanta Magazine,
The central limit theorem started as a bar trick for 18th-century gamblers. Now scientists rely on it every day. Daniela Witten, Professor of Biostatistics and Statistics at the University of Washington, is quoted.
Dr. Elizabeth Halloran, expert in vaccine trial design and quantitative methods for infectious diseases, transitions to emerita
Fred Hutch News,
Infectious disease modeling pioneer helped outline modern precepts for design and analysis of vaccine trials, causal inference with interference; shaped a generation of infectious disease scientists. M. Elizabeth Halloran was a professor with the University of Washington Department of Biostatistics and founder of the Summer Institute in Statistics and Modeling for Infectious Diseases (SISMID).
Understanding Cancer Diagnosis: An Expert Discussion with Dr. Kathleen Kerr
Girl Doc Survival Guide Podcast,
In this podcast episode Kathleen Kerr, a Professor of Biostatistics at the University of Washington, discusses overdiagnosis and medical decision making. Kerr delves into how patients perceive mammogram results, the difference between overdiagnosis and overcalling, and the challenges pathologists face in diagnosing cancer. She also shares findings from her research on the influence of prior opinions on second diagnoses and the cognitive processes involved in interpreting pathology images. The discussion highlights the complexities and subjectivity in pathology diagnoses and the implications for patient care.
Vibrent Health Joins a Landmark BARDA-Funded Large-Scale Hybrid/Remote Decentralized Clinical Research Study
businesswire,
Vibrent Health, a leading software-as-a-service (SaaS) data company in the field of precision medicine research, is collaborating with Fred Hutch Cancer Center on critical correlates of protection research. Peter Gilbert, principle Hutch investigator and University of Washington professor of biostatistics, is quoted: ""This study expands access, enhances flexibility of collecting high-quality data, and accelerates the development of next-generation therapeutics and prevention agents...By identifying and validating correlates of protection, this research not only informs the development of more targeted and effective treatments for infectious diseases but also establishes a framework that can be applied to a wide range of clinical trials, improving outcomes and speeding up the path to approval."